scholarly journals Donor Genotype and Susceptibility to Transplant-Associated Thrombotic Microangiopathy

2017 ◽  
Vol 23 (3) ◽  
pp. S234-S235 ◽  
Author(s):  
Sonata Jodele ◽  
Kejian Zhang ◽  
Christopher E. Dandoy ◽  
Kasiani C. Myers ◽  
Adam Lane ◽  
...  
Keyword(s):  
Thrombotic Microangiopathy ◽  
Donor Genotype

Complement-mediated thrombotic microangiopathy or sepsis with disseminated intravascular coagulation -what is primary?

2019 ◽  
Vol 23 (3) ◽  
pp. 78-83
Author(s):  
F. U. Dzgoeva ◽  
N. L. Kozlovskaya ◽  
T. L. Bestaeva ◽  
A. M. Kuchieva ◽  
G. G. Bekuzarova
Keyword(s):  
Disseminated Intravascular Coagulation ◽  
Thrombotic Microangiopathy ◽  
Intravascular Coagulation

scholarly journals Thrombotic microangiopathy in dasatinib-treated patients with chronic myeloid leukemia

2019 ◽  
Vol 4 (1-2) ◽  
pp. 41-45 ◽  
Author(s):  
Takeo Koshida ◽  
Sylvia Wu ◽  
Hitoshi Suzuki ◽  
Rimda Wanchoo ◽  
Vanesa Bijol ◽  
...  
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Tyrosine Kinase Inhibitors ◽  
Thrombotic Microangiopathy ◽  
Myeloid Leukemia ◽  
Kinase Inhibitors ◽  
Kidney Biopsy ◽  
Kinase Inhibitor ◽  
Target Effect

Dasatinib is the second-generation tyrosine kinase inhibitor used in the treatment of chronic myeloid leukemia. Proteinuria has been reported with this agent. We describe two kidney biopsy–proven cases of dasatinib-induced thrombotic microangiopathy that responded to stoppage of dasatinib and using an alternate tyrosine kinase inhibitor. Certain specific tyrosine kinase inhibitors lead to endothelial injury and renal-limited thrombotic microangiopathy. Hematologists and nephrologists need to be familiar with this off-target effect of dasatinib.

Sign in / Sign up

Export Citation Format

Share Document